Aims Cardiac resynchronization therapy (CRT) is an established treatment for heart failure.
There is contradictory evidence whether defibrillator capability improves prognosis in …

Aims The choice of resynchronization therapy between with (CRT-D) and without (CRT-P) a
defibrillator remains a contentious issue. Cause-of-death analysis among CRT-P, compared …

Aims There are limited and contradictory data on the effects of CRT with implantable
cardioverter defibrillator (CRT‐D) on mortality as compared with CRT with pacemaker (CRT …

Aims The very long-term outcome of patients who survive the first few years after receiving
cardiac resynchronization therapy (CRT) has not been well described thus far. We aimed to …

Aims Randomized controlled trials have shown that cardiac resynchronization therapy
(CRT) prolongs survival in patients with heart failure. No studies have explored survival after …

Aims In candidates for cardiac resynchronization therapy (CRT), the choice between
pacemaker (CRT-P) and defibrillator (CRT-D) implantation is still debated. We compared the …

Background Cardiac resynchronization therapy (CRT) is an effective treatment option for
systolic heart failure, but the benefit of an additional implantable cardioverter-defibrillator …

Aims While data from randomized trials suggest a declining incidence of sudden cardiac
death (SCD) among heart failure patients, the extent to which such a trend is present among …

Aims Cardiac resynchronization therapy (CRT) improves symptoms, left ventricular function,
and survival in patients with heart failure (HF) and wide QRS. The benefit of adding …

Aims Mortality after cardiac resynchronization therapy (CRT) is difficult to predict. We sought
to design and validate a simple prognostic score for patients implanted with CRT, based on …